CD160Ig Fusion Protein Targets a Novel Costimulatory Pathway and Prolongs Allograft Survival

DSpace/Manakin Repository

CD160Ig Fusion Protein Targets a Novel Costimulatory Pathway and Prolongs Allograft Survival

Citable link to this page

 

 
Title: CD160Ig Fusion Protein Targets a Novel Costimulatory Pathway and Prolongs Allograft Survival
Author: D’Addio, Francesca; Ueno, Takuya; Clarkson, Michael; Zhu, Baogong; Vergani, Andrea; Freeman, Gordon James; Sayegh, Mohamed Hassan; Ansari, Mohammed Javeed I.; Fiorina, Paolo; Habicht, Antje

Note: Order does not necessarily reflect citation order of authors.

Citation: D’Addio, Francesca, Takuya Ueno, Michael Clarkson, Baogong Zhu, Andrea Vergani, Gordon J. Freeman, Mohamed H. Sayegh, Mohammed Javeed I. Ansari, Paolo Fiorina, and Antje Habicht. 2013. Cd160ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival. PLoS ONE 8(4): e60391.
Full Text & Related Files:
Abstract: CD160 is a cell surface molecule expressed by most NK cells and approximately 50% of CD8+ cytotoxic T lymphocytes. Engagement of CD160 by MHC class-I directly triggers a costimulatory signal to TCR-induced proliferation, cytokine production and cytotoxic effector functions. The role of CD160 in alloimmunity is unknown. Using a newly generated CD160 fusion protein (CD160Ig) we examined the role of the novel costimulatory molecule CD160 in mediating CD4+ or CD8+ T cell driven allograft rejection. CD160Ig inhibits alloreactive CD8+ T cell proliferation and IFN-γ production in vitro, in particular in the absence of CD28 costimulation. Consequently CD160Ig prolongs fully mismatched cardiac allograft survival in CD4−/−, CD28−/− knockout and CTLA4Ig treated WT recipients, but not in WT or CD8−/− knockout recipients. The prolonged cardiac allograft survival is associated with reduced alloreactive CD8+ T cell proliferation, effector/memory responses and alloreactive IFN-γ production. Thus, CD160 signaling is particularly important in CD28-independent effector/memory CD8+ alloreactive T cell activation in vivo and therefore may serve as a novel target for prevention of allograft rejection.
Published Version: doi:10.1371/journal.pone.0060391
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3617215/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:11365693
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters